Phase I Clinical Trial of DS-7423 - Evaluation of Safety and Pharmacokinetics of DS-7423 in Japanese Patients With Advanced Solid Tumors
Latest Information Update: 03 Jun 2017
At a glance
- Drugs DS 7423 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 02 Jun 2017 Results (n=69) of this and other phase I,first in human study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 22 Sep 2015 New trial record